BMS, Ono expand cancer immunotherapy pact
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Ono Pharmaceuticals are joining up under a collaborative deal to develop a number of immunotherapies for various cancer indications in Japan, South Korea and Taiwan.